6533b874fe1ef96bd12d6316

RESEARCH PRODUCT

Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer.

Aleksi LahdesmakiUlf GunnarssonChristian KerstenAnnika ÅLgarsMilada CvancerovaKristina StenstedtCaj HaglundJohanna Louhimo

subject

AdultMalemedicine.medical_specialtyColorectal cancerIncreased C-reactive proteinDiseaseGastroenterologyInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingStage (cooking)Stage specificSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overbusiness.industryElevated crpRetrospective cohort studyHematologyGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurgerySurvival RateC-Reactive ProteinOncologyLymphatic MetastasisColonic NeoplasmsFemaleNeoplasm GradingbusinessFollow-Up Studies

description

To characterize the stage-specific prognostic relevance of preoperative systemic inflammatory response, defined by C-reactive protein (CRP), in colon cancer (CC) patients.Data from CC patients operated on from 1998 to 2007 at three hospitals from three different Nordic countries were collected retrospectively from national registries, local databases and/or patient records. Patients with emergency surgery, infection or auto-immune disease were excluded. Associations between clinical or histopathological variables and CRP were assessed. Patients were followed from the date of surgery to death or end of follow-up. Disease-specific survival (DSS) was the main endpoint.In total, 525 patients with age and stage distributions which were representative for CC patients were included. None of the patients was lost to follow-up. Age, TNM Stage, WHO differentiation grade and right-sided tumor location significantly associated with elevated CRP values, in contrast to postoperative morbidity, which did not. CRP levels were found to be a strong prognostic factor for DSS in CC. The risk of death due to CC was augmented with increasing levels of CRP in every stage of operated CC. Both short- and long-term DSS were impaired. The sub-hazard ratios for CRP-levels above 60 mg/L were 7.37 (CI 2.65-20.5) for stage I+ II, compared to 3.29 (CI 1.30-8.29) for stage III and 2.24 (CI 1.16-4.35) for stage IV.Increase of CRP concentrations correlate with clinically relevant poorer disease-specific survival in each stage of CC.

10.3109/0284186x.2013.835494https://pubmed.ncbi.nlm.nih.gov/24102179